Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 5/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.46 |
| ▸ | APP | P05067 | 6/20 | 0.42 |
| ▸ | ESR1 | P03372 | 4/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.40 |
| ▸ | ESRRG | P62508 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975499 | 0.86 | HSD17B1 (0.48) | HSD17B1HSD17B2APPESR1ESR2 | |
| SCHEMBL14278458 | 0.86 | CYP2A6 (0.45) | HSD17B1HSD17B2SLC5A2SLC5A1 | |
| SCHEMBL146792 | 0.84 | APP (0.42) | HSD17B1HSD17B2APPSLC5A2SLC5A1 | |
| SCHEMBL148158 | 0.83 | CYP2A6 (0.37) | HSD17B1HSD17B2SLC5A2SLC5A1 | |
| SCHEMBL147405 | 0.82 | RORC (0.42) | HSD17B1HSD17B2SLC5A2SLC5A1 | |
| SCHEMBL148014 | 0.82 | SLC5A2 (0.41) | HSD17B1HSD17B2SLC5A2SLC5A1 | |
| SCHEMBL144713 | 0.82 | SLC5A2 (0.41) | HSD17B1HSD17B2SLC5A2SLC5A1 | |
| SCHEMBL147396 | 0.81 | APP (0.49) | APP | |
| SCHEMBL156337 | 0.81 | SLC5A2 (0.40) | SLC5A2SLC5A1 | |
| SCHEMBL147481 | 0.81 | SLC5A2 (0.40) | HSD17B1HSD17B2SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HSD17B1 268/4885HSD17B2 195/4885APP 2684/4885 |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HSD17B1 268/4885HSD17B2 195/4885APP 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.